This content is in French.
TNBC: exploring the global landscape of biomarkers and therapeutic prospects
22 octobre 2025
By Lila Rouland | Published on October 22, 2025 | 3 min readTriple-negative breast cancer (TNBC) is characterized by the absence of hormonal receptors (ER, PR) and the HER2 protein. This particularity significantly limits targeted therapeutic options, leading to a poor prognosis marked by high recurrence and low overall survival rates. Given the biological heterogeneity of TNBC, global research ef
By Lila Rouland | Published on October 22, 2025 | 3 min read
Triple-negative breast cancer (TNBC) is characterized by the absence of hormonal receptors (ER, PR) and the HER2 protein. This particularity significantly limits targeted therapeutic options, leading to a poor prognosis marked by high recurrence and low overall survival rates. Given the biological heterogeneity of TNBC, global research efforts are increasingly focused on identifying reliable biomarkers to improve diagnosis, patient stratification, and treatment strategies.
Triple-negative breast cancer (TNBC) is characterized by the absence of hormonal receptors (ER, PR) and the HER2 protein. This particularity significantly limits targeted therapeutic options, leading to a poor prognosis marked by high recurrence and low overall survival rates. Given the biological heterogeneity of TNBC, global research efforts are increasingly focused on identifying reliable biomarkers to improve diagnosis, patient stratification, and treatment strategies.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Wang X, et al . (2024) Global biomarker trends in triple-negative breast cancer research: a bibliometric analysis. Int J Surg. 2024 Jun;110:7962–7983.
View the source
